Company Description

GNOMX's next-generation platform provides high-specificity, low cross-reactivity, and compatibility with rapid diagnostic assays that are highly advantageous compared to any existing diagnostic or prognostic technology (e.g., enabling diagnostics long after original pathogen has vanished).